AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platf ...

Core Viewpoint - Red Light Holland Corp. has engaged Kala Bio's Researgency.ai platform to enhance the clinical development strategy for its psilocybin drug candidate PEX010, aiming to leverage AI for improved research capabilities and accelerated drug development timelines [1][3][7]. Group 1: Company Developments - Red Light has entered a definitive arrangement agreement to acquire Filament Health Corp., which includes a portfolio of 76 issued patents across 15 patent families, significantly enhancing its intellectual property in botanical psilocybin drug development [2]. - PEX010 is currently supplied to over 70 clinical research sites globally and is being studied for various mental health conditions, including alcohol use disorder and treatment-resistant depression [4][8]. - The drug candidate has received authorization for clinical trials from both Health Canada and the U.S. Food and Drug Administration, demonstrating positive Phase 2 clinical data in alcohol use disorder [5]. Group 2: Strategic Rationale - The integration of the Researgency.ai platform is a strategic move for Red Light to enhance its psychedelic drug development capabilities, focusing on research planning, scenario simulation, and protocol optimization [3][6]. - The Researgency.ai platform is designed to create autonomous research loops that can generate and optimize study scenarios, compressing timelines and expanding viable options for clinical trials [6][11]. Group 3: Management Commentary - Management emphasizes that utilizing Kala Bio's AI platform is a natural progression in building a leading psychedelic drug development operation, aiming to strengthen study designs and accelerate decision-making processes [7]. - The CEO of Filament Health highlights the importance of advanced analytical tools in evaluating clinical development strategies as the program evolves [7]. - Kala Bio's CEO notes that the deployment of Researgency.ai addresses high-value, data-intensive challenges in psychedelic drug development, which can significantly impact clinical scenario evaluations [7].

Core Insights - Younet.ai's Researgency.ai platform aims to revolutionize biotech R&D by applying autonomous research principles, validated by the recent release of AutoResearch by Andrej Karpathy [1][2][3] Group 1: AutoResearch and Its Implications - AutoResearch is an open-source tool that allows AI agents to autonomously conduct over 100 machine-learning experiments overnight on a single GPU, significantly increasing research velocity through continuous iteration [2][4] - The tool demonstrates the potential for autonomous research to transform life-sciences planning and decision-making, aligning with Younet.ai's vision for Researgency.ai [2][5] Group 2: Researgency.ai Development - Researgency.ai is being developed in collaboration with Kala Bio, Inc. (NASDAQ: KALA) to implement autonomous research loops in biotechnology R&D, translating the concept of "100 experiments overnight" into "100 study scenarios overnight" [5][10] - The platform is designed to enable agents to autonomously plan, simulate, and optimize research scenarios, thereby enhancing the efficiency of biotech research workflows [5][13] Group 3: The Agentic Research Loop - The agentic research loop consists of three phases: defining objectives with human input, executing autonomous agent loops for scenario generation and evaluation, and conducting morning reviews for strategic decision-making [6][8] - This approach aims to shift life-sciences organizations from manual, sequential planning to continuous, parallel scenario exploration, compressing timelines and expanding viable options [11][12] Group 4: Real-World Applications and Benefits - A public example from Shopify's CEO indicates that using AutoResearch led to a 19% improvement in validation scores, showcasing the effectiveness of autonomous iteration in real-world applications [9][10] - Younet.ai believes that agentic approaches can yield compounding improvements in complex optimization problems, which Researgency.ai seeks to apply in life-sciences contexts [10]

Core Insights - KALA BIO, Inc. is transitioning from a clinical-stage biotech to a dual-engine growth company with a proprietary drug pipeline and an AI platform targeting the $180+ billion AI-in-healthcare market [1][6] - The company is set to launch its first commercial AI product, Researgency.ai, within approximately 14 days, marking a significant step in its go-to-market strategy [2][8] Company Strategy - KALA aims to build a dedicated AI infrastructure for the biotech industry, similar to how Palantir operates in data analytics for various sectors [1][3] - The Researgency.ai platform is designed to address critical pain points in biotech and pharma, such as repetitive workflows, compliance documentation, and costly delays in drug development [4][5] Market Opportunity - The global AI-in-healthcare market is projected to exceed $180 billion by 2030, with a significant increase in enterprise interest in agentic AI systems, as evidenced by a 1,445% surge in inquiries from Q1 2024 to Q2 2025 [3] - KALA is focusing on the biotech and pharmaceutical sectors, which are characterized by high data intensity and compliance requirements, positioning itself as a key player in this niche market [3][4] Product Capabilities - The Researgency.ai platform will enable companies to design, deploy, and improve AI agents for various applications, including research intelligence, clinical trials, regulatory compliance, safety monitoring, and commercial launch preparations [5] Investor Implications - The transformation of KALA from a single-drug focus to a platform company with recurring revenue potential is expected to attract a broader range of investors, as it can now serve multiple clients in the biotech and pharma industries [6][8] - Early investors in successful platform companies have historically seen significant returns, indicating a promising outlook for KALA's future [7]